Remtolumab

A4DAB223 | Phase-II
IL17A;TNF/TNFA
G1;G1 / None
Abbott Laboratories Abbvie
Phase-II
Bispecific Dual Variable Domain IG
ABT-122 ABT122 ABT 122
—
Avg A4D Score
-0.6716
Score Range
-0.75 to -0.52
Structures
6
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB223_6cr1_H_L 6cr1 100% -0.7527 8.5 4.0 -0.5561 -0.7771
A4DAB223_4nyl_C_D 4nyl 100% -0.7347 6.5 4.0 -0.5298 -0.7609
A4DAB223_4nyl_A_B 4nyl 100% -0.517 6.5 4.0 -0.4855 -0.5226
A4DAB223_4nyl_E_F 4nyl 100% -0.594 7.0 4.0 -0.5317 -0.6066
A4DAB223_3wd5_H_L 3wd5 99% -0.7045 6.5 4.0 -0.5526 -0.7238
A4DAB223_4nyl_H_L 4nyl 100% -0.7269 6.5 4.0 -0.4738 -0.7593